Clinical efficacy of telbivudine and lamivudine in HBeAg positive chronic hepatitis B patients
10.13699/j.cnki.1001-6821.2014.06.005
- VernacularTitle:替比夫定和拉米夫定对 e抗原阳性慢性乙型肝炎的临床疗效
- Author:
Yun-Cai WANG
1
;
Li ZHANG
;
Hao LI
;
Chong CHEN
;
Ai-Guo WANG
Author Information
1. 重庆市开县人民医院 感染科
- Keywords:
telbivudine;
HBeAg positive;
chronic hepatitis B;
HBeAg seroconversion;
lamivudine
- From:
The Chinese Journal of Clinical Pharmacology
2014;(6):487-489
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of telbivudine in HBeAg positive chronic hepatitis B patients.Methods The clinical data of 120 patients with HBeAg positive chronic hepatitis B treated with lamivudine and telbivudine in our hospital were collected.The HBV DNA level and HBeAg seroconversion rate of lamivudine group and telbivudine group at the 4th, 8th, 12th, 24th and 48th week were compared as well as differ-ences of adverse reactions during treatment.Results The result showed that there were no statistical differences between the groups at the 4th, 8th and 12 th week ( P>0.05 ).Compared with the lamivudine group , the HBV-DNA level in telbivudine group was significantly lower while E an-tigen seroconversion rate was significantly higher at the 24 th and 48 th week , the difference between groups were statistically significant ( P <0.05 ).The incidence of adverse reactions between the two groups had no statistical difference ( P>0.05 ).In telbivudine group , the HBeAg seroconversion rate of patients under the age of 40 was 49% at the 48 th week of treatment while it was 9.5%in patients over 40 , the difference between two groups was statistically significant ( P<0.05 ).Conclusion Petients under the age of 40 with HBeAg positive chronic hepatitis B treated with telbivudine has a higher HBeAg seroconversion rate and mild adverse reactions.
